The global market for human vaccines has experienced strong growth in the past few years, and R&D departments at many pharmaceutical companies are working on new prophylactics, some of which may see near-term marketing. What illnesses may see a vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine market? This Kalorama Information report What's Next in Vaccines? examines and estimates the market for vaccines that have yet to be launched, including the following target areas:
Some of these vaccines may see success; some could be the blockbusters of the future. For marketers and industry watchers a knowledge of all of the potential vaccines will be important to understand how pharma is seeking to renew bottom line with aggressive prophylactic strategies, and who the winners and losers in the near future may be. Alison Sahoo has looked at the vaccine market three times in as many years for Kalorama Information, and in this report applies a knowledge of what companies have done in the past to potential efforts.
There are a number of trends that will impact the industry that market watchers will want to know about, and Kalorama Information has covered these trends; including: New Vaccine Technologies, DNA Vaccination, Innovative Delivery Systems, Edible Vaccines, Vaccine Patches, Funding Shortfalls. The report also discusses vaccine manufacturing methods and the approval process. In addition, the report focuses on the emerging vaccine activities of the following companies
This report provides forecasted revenues for products in development out to 2020. The report does not does not cover indication expansions of existing vaccine products, nor does it cover vaccines for which products currently exist and are widely available, but may need improvement. Development of vaccines that incorporate new
production methods (such as the migration of chicken eggs to mammal, yeast or other cells) is also excluded. Cancer vaccines are excluded as Kalorama has an entire report on this topic.
Sales estimates for each market segment represent global revenues and are expressed in current dollars. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources.
New York, February 18, 2010 — In the not-too-distant future we could see diabetes, the seventh leading cause of death in the U.S., treated with a vaccine. Several vaccine candidates are in the pipeline, creating a possible $2.4 billion market for diabetes vaccine products by 2020, according to healthcare market research publisher Kalorama Information, who recently published a survey of emerging vaccine products titled: What’s Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline.
Type I diabetes currently afflicts 35,000 people in the U.S. and about 700,000 people worldwide each year. Type II diabetes affects more than 16 million Americans and over 200 million people worldwide.
Currently, other than a humanized anti-CD3 antibody with considerable side effects, there is no other means to reverse new-onset type 1 diabetes. People with type II diabetes must control their blood sugar levels with diet and exercise, and approximately 78% also take prescription medications to help control their diabetes. However, they remain at risk for a large number of associated conditions including foot ulcers, heart disease, kidney failure, and various skin conditions.
“Diabetes is a debilitating disease and a growing problem as waistlines continue to expand,” said Bruce Carlson, publisher of Kalorama Information. “This is a desirable market for any drug maker, and it’s not surprising that the pipeline is full.”
There are at least seven diabetes vaccine candidates in development. Most are in Phase I testing and address type 1 diabetes. But one being developed by the Swedish company Diamyd Medical is currently in a global Phase III trial, which includes 640 children and adolescents newly diagnosed with type 1 diabetes. The purpose of the Phase III trial is to confirm and evaluate the ability of the Diamyd vaccine to arrest or slow the autoimmune destruction of the body's insulin-producing cells, thereby preserving the body's own ability to produce insulin. Initial analysis of data from the Phase II trial showed that patients treated with the Diamyd vaccine early after diagnosis have a clearly better diabetes status compared to the corresponding placebo group, 4 years after the injections.
Kalorama predicts a $100 million market from diabetes vaccines by 2012 as the first product currently in Phase III trials enters the market, with growth amounting to $2.4 billion by 2020 as other products reach market.
Kalorama Information’s What’s Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline. forecasts emerging vaccine markets through 2020, previews the product pipeline and details the major players in the industry.
About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.